Loading
Loading
Growth Hormone & Secretagogues · 1mg
Janoshik-tested · 10 vials per kit
IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1 with a modified N-terminus studied in preclinical research for its anabolic and tissue-growth properties. The LR3 modification reduces IGF-binding protein affinity, extending biological activity. Research has examined its potential to promote cellular proliferation, differentiation, protein synthesis, and inhibit apoptosis across multiple tissue types.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
IGF-1 LR3
Long R3 Insulin-Like Growth Factor-1
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of human insulin-like growth factor-1 with two structural modifications: substitution of glutamate-3 by arginine (R3), and addition of a 13-amino-acid extension at the N-terminus. These changes reduce binding affinity for IGF-binding proteins (IGFBPs) by approximately 2-3 fold, prolonging half-life from ~10 minutes to ~20-30 hours compared to native IGF-1.
IGF-1 LR3 activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that shares structural homology with the insulin receptor. Ligand binding triggers autophosphorylation and activation of IRS-1/IRS-2 adapter proteins, leading to PI3K/Akt signalling (protein synthesis, anti-apoptosis, glucose transport) and MAPK/ERK signalling (cell proliferation, differentiation). In skeletal muscle, IGF-1R activation stimulates protein synthesis, satellite cell activation, glucose uptake independent of insulin, and anti-catabolic gene expression.
Skeletal muscle hypertrophy and repair, satellite cell biology, body composition research, post-injury muscle recovery, and anabolic muscle signalling. Also studied for neuroprotection (IGF-1R is expressed in neurons and promotes neuronal survival), bone metabolism, and insulin sensitivity research. The extended half-life of the LR3 form makes it preferable to native IGF-1 for most research protocols.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
